TELA Bio, Inc. (TELA) is an innovative commercial-stage medical technology firm focused on the design, development, and marketing of a novel class of tissue reinforcement materials aimed at the $3 billion soft tissue reconstruction market. TELA Bio's products are used in essential surgical procedures in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Based in Malvern, Pennsylvania, the company was founded in 2012 by a team of experienced healthcare and medical device professionals. TELA Bio's primary objective is to provide more cost-effective, biologically relevant options for surgeons and patients than the existing synthetic materials. Its mission is 'Restoring the Body's Natural Strength' and this is perfectly reflected in their major rank of products called 'OviTex Reinforced BioScaffolds'.
The OviTex products represent the first of a new category of surgical implants made from a unique blend of materials. They are the result of a sophisticated manufacturing process that seamlessly integrates polymer and biologic materials, providing unprecedented mechanical and biological properties that help surgeons restore the body's natural anatomy.
Furthermore, TELA Bio has launched a clinical study, 'Bravo', that showcases the safety and performance of OviTex - a study that is currently ongoing in multiple centers across the US. The Bravo study is expected to be one of the largest prospective, multicenter clinical studies in hernia repair with long-term follow-up of patients.
TELA Bio operates in a competitive landscape, but their innovative products have already shown wide acceptance in the medical community. The business model emphasizes working closely with surgeons to develop and commercialize its biologic products and surgical implants for hernia repair.
TELA Bio is a forward-thinking company, subject to stringent regulations encountered by all medical device manufacturers. Needless to say, their commitment is to meet and surpass these regulatory requirements.
The organization has a robust Intellectual Property (IP) portfolio, with a large number of patents and patent applications intended to protect its technology around the world. Its partnership with Aroa Biosurgery Limited, a soft tissue regeneration company, has allowed TELA Bio to access invaluable intellectual property and know-how in the field of tissue manipulation.
TELA Bio's vast market potential, clear product differentiation, and growing sales trajectory make it a notably unique player in the medical device industry. The company remains committed to revolutionizing soft tissue repair through biomaterial science, showing its dedication to improving outcomes for patients while reducing costs for healthcare systems.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Craig-Hallum has initiated coverage on TELA Bio (TELA) with a Buy rating and a $2.00 price target, signaling renewed confidence in the company's potential. Despite being considered 7.9% undervalued by GuruFocus's GF Value, the company is currently unprofitable and cash-flow negative, leading to a GF Score of 63/100. Insider buying activity suggests confidence from those within the company, but financial strength and profitability remain key concerns for investors.
_07_03_2026_03_50_21_133108.jpg)
Joseph H. Capper, an insider at TELA Bio, Inc. (NASDAQ:TELA), acquired 75,000 shares of the company's stock in two open-market purchases between September 14 and 15, 2026. The shares were bought at prices ranging from $1.02 to $1.06 each. Following these transactions, Capper's total holdings in TELA Bio increased to 104,827 shares, representing approximately 71.5% of his overall stake.
Joseph Capper, a Director at TELA Bio Inc (TELA), recently purchased 75,000 shares of the company's stock, increasing his total ownership to 104,827 shares. This open-market transaction, valued at $78,750 at a price of $1.05 per share, signals a bullish outlook from an insider. The stock is considered "Modestly Undervalued" according to GuruFocus's GF Value, and insider buying has been consistent over the past year with 4 buys and no sells.
TELA Bio CEO Heather Getz recently purchased 12,500 shares of company stock for $8,311, increasing her direct holdings to 532,500 shares. This insider purchase follows a 15.5% stock gain over the past week, though shares are down 54% over the past year. The company also reported a second-quarter earnings miss, withdrew its 2026 revenue guidance, but saw improvements in gross margin and growth in OviTex unit volume, international sales, and LIQUIFIX revenue, despite a decline in its plastic and reconstructive surgery portfolio.